The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe

被引:26
|
作者
Armuzzi, Alessandro [1 ]
Tarallo, Miriam [2 ]
Lucas, James [3 ]
Bluff, Daniel [3 ]
Hoskin, Benjamin [3 ]
Bargo, Danielle [4 ]
Cappelleri, Joseph C. [5 ]
Salese, Leonardo [6 ]
DaCosta DiBonaventura, Marco [4 ]
机构
[1] Univ Cattolica Sacro Cuore, Fdn Policlin A Gemelli IRCCS, Rome, Italy
[2] Pfizer Inc, Rome, Italy
[3] Adelphi Real World, Macclesfield, Cheshire, England
[4] Pfizer Inc, New York, NY 10017 USA
[5] Pfizer Inc, Groton, CT 06340 USA
[6] Pfizer Inc, Collegeville, PA USA
关键词
Ulcerative colitis; Quality of life; Work impairment; Activity impairment; Patient-reported outcomes; QUALITY-OF-LIFE; INFLAMMATORY-BOWEL-DISEASE; BURDEN; PHYSICIAN; COSTS;
D O I
10.1186/s12876-020-1164-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Patients with ulcerative colitis (UC) experience periods of recurring and episodic clinical signs and symptoms. This study sought to establish the association between disease activity and health-related quality of life (HRQoL) and other patient-reported outcomes. Methods United States (US) and European Union 5 ([EU5]; i.e., France, Germany, Italy, Spain, and the United Kingdom) data from the 2015 and 2017 Adelphi Inflammatory Bowel Disease-Specific Programme (IBD-DSP) were used. The IBD-DSP is a database of retrospective patient chart information integrated with patient survey data (EuroQoL-5 Dimensions [EQ-5D], Short Quality of Life in Inflammatory Bowel Disease Questionnaire [SIBDQ], and Work Productivity and Activity Impairment-Ulcerative Colitis [WPAI-UC] questionnaire). Using available chart information, physicians classified their moderate-to-severe patients into one of the following categories: remission with a Mayo endoscopic score = 0 ("deep remission"), remission without a Mayo endoscopic score = 0 ("remission"), or active disease. Differences among disease activity categories with respect to patient-reported outcomes were analyzed using generalized linear models, controlling for confounding variables. Results N = 289 and N = 1037 patient charts with linked surveys were included from the US and EU5, respectively. The disease activity distribution was as follows: active disease = 40.1% (US) and 33.6% (EU5); remission = 48.0 and 53.0%; deep remission = 11.9 and 13.3%. Patients with active disease reported significantly lower levels of EQ-5D health state utilities (adjusted mean [AdjM] = 0.87 [US] and 0.78 [EU5]) compared with remission (AdjM = 0.92 and 0.91) and deep remission (AdjM = 0.93 and 0.91) (all P < 0.05 compared with active disease within each region). Similar findings were observed with the scores from the SIBDQ and the WPAI-UC. No significant differences were observed between remission categories. Conclusions Among patients with moderate-to-severe UC in the US and EU5, active disease was associated with significant impairments in HRQoL, work and leisure activities. These results reinforce the importance, to both the patient and society, of achieving some level of remission to restore generic and disease-related HRQoL and one's ability to work productively.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Biologics for the treatment of moderate-to-severe ulcerative colitis in pediatric patients
    Albenberg, Lindsey G.
    Mamula, Petar
    Kelsen, Judith R.
    [J]. PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2012, 3 : 51 - 58
  • [32] PATIENT-REPORTED QUALITY OF LIFE DURING GOLIMUMABINDUCTION FOR MODERATE TO SEVERE ULCERATIVE COLITIS IN THE UNITED KINGDOM: RESULTS FROM THE GO-COLITIS STUDY
    Irving, P.
    Sebastian, S.
    Probert, C.
    Gaya, D.
    Hamlin, P. J.
    Gillespie, G.
    Tate, H.
    Wheeler, C.
    [J]. GUT, 2017, 66 : A8 - A8
  • [33] GOLIMUMAB INDUCTION FOR MODERATE TO SEVERE ULCERATIVE COLITIS: PATIENT-REPORTED OUTCOMES OF PARTIAL MAYO SCORE RESULTS FROM THE GO-COLITIS STUDY
    Sebastian, S.
    Probert, C.
    Gaya, D.
    Hamlin, P. J.
    Irving, P.
    Gillespie, G.
    Tate, H.
    Wheeler, C.
    [J]. GUT, 2017, 66 : A122 - A123
  • [34] Psychometric validation and interpretation of a patient-reported outcomes instrument to assess bowel urgency among adults with moderate to severe Ulcerative Colitis
    Dubinsky, M. C.
    Delbecque, L.
    Lewis, J.
    Hunter, T.
    Shan, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I220 - I220
  • [35] PSYCHOMETRIC VALIDATION AND INTERPRETATION OF A PATIENT-REPORTED OUTCOMES INSTRUMENT TO ASSESS BOWEL URGENCY AMONG ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
    Dubinsky, Marla
    Delbecque, Laure
    Lewis, James D.
    Gibble, Theresa H.
    Shan, Mingyang
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S855 - S856
  • [36] Characterization of Patient-reported Outcomes in moderate to severe Psoriasis
    Radtke, M. A.
    Schmitt-Rau, K. H.
    Krenzer, S.
    Augustin, M.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 126 - 126
  • [37] United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) survey
    Travis, S.
    Bleakman, A.
    Dubinsky, M.
    Rubin, D.
    Panaccione, R.
    Hibi, T.
    Kayhan, C.
    Gibble, T. H.
    Sapin, C.
    Flynn, E.
    Atkinson, C.
    Schreiber, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 637 - 638
  • [38] Characterization of Patient-Reported Outcomes in Moderate to Severe Psoriasis
    Krenzer, Stefanie
    Radtke, Marc
    Schmitt-Rau, Karlheinz
    Augustin, Matthias
    [J]. DERMATOLOGY, 2011, 223 (01) : 80 - 86
  • [39] UNITED STATES AND EUROPEAN PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS ON SEXUAL ACTIVITY: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
    Travis, Simon P.
    Bleakman, Alison Potts
    Dubinsky, Marla C.
    Rubin, David T.
    Panaccione, Remo
    Hibi, Toshifumi
    Kayhan, Cem
    Gibble, Theresa H.
    Sapin, Christophe
    Flynn, Eoin J.
    Atkinson, Christian
    Schreiber, Stefan
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S237 - S237
  • [40] The Association Between Patient-Reported Outcomes and Faecal Calprotectin in Ulcerative Colitis: Gut "Feeling" Over IBD "Control"?
    Nigam, Gaurav B.
    Limdi, Jimmy K.
    Parsons, Joanna
    Hamdy, Shaheen
    Vasant, Dipesh
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S340 - S341